Valuation dashboard for Cibus, Inc. (CBUS) with P/E N/A, P/B 8.09, EV/EBITDA -2.29 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name.
Analysis Summary
Cibus, Inc. reported revenue of $3.6M in the most recent fiscal year, growing at a 5-year CAGR of -31.3%.
Trailing-twelve-month margins: gross margin 45.7%, operating margin -12.4%, net margin -22.6%.
At the current price of $1.51, CBUS has negative trailing earnings (P/E not meaningful) and an ROE of -320.60%. Market capitalisation stands at $115M.
Balance sheet quality for CBUS: current ratio of 0.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 8.09 |
| EV / EBITDA | -2.29 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CBUS | Cibus, Inc. | $115M | 8.09 | -320.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.51 |
| Market Cap | $115M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -320.60% |
| Return on Invested Capital | -17.82% |
| Return on Assets | -31.33% |
| Gross Margin | 45.73% |
| Operating Margin | -1240.90% |
| Net Margin | -2258.89% |
Related companies: ACRV · BMEA · CAMP · IMUX · MNOV · PMVP · RLMD
Explore sector: Healthcare · Biotechnology
More sections of CBUS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks